Naming and labelling of biologicals – a survey of US physicians’ perspectives

Author(s): Harry L Gewanter, MD, FAAP, FACR, Michael S Reilly, Esq

Introduction: The US Food and Drug Association (FDA) released its requirements for the non-proprietary naming of biological products in January 2017. Before the FDA’s release, the Alliance for Safe Biologic Medicines (ASBM) asked physicians for their views on the labelling and naming of biosimilar medicines. Study objectives: To determine the opinions of physicians who prescribe […]

Read more →